Metrion Biosciences’ new cardiac safety White Paper is now available to download here.

You can contact our team to discuss our high quality ion channel services via info@metrionbiosciences.com.

Leaders in Ion Channel Biology

Welcome to Metrion Biosciences

Metrion Biosciences is a UK-based Contract Research Organization (CRO) focussed on delivering a range of high quality ion channel drug discovery services. We provide highly skilled electrophysiology screening services to support client medicinal chemistry optimisation programmes, CiPA compliant cardiac safety profiling assays, neuroscience assays and translational assays. Working closely with our collaborators Assay.Works and Concept Life Sciences we also offer an expert integrated drug discovery service.

Metrion offers flexible business models according to the scope of each programme, with both fee-for-service and collaborative options available.

Our Expertise

Metrion has assembled a team of highly expert and dedicated ion channel screening specialists to support diverse ion channel drug discovery projects and modern safety assessment research. We combine in depth target class knowledge and high quality screening assays with experienced and collaborative project managers to keep your research focused upon meeting both objectives and timelines.

Our Services

Ion Channel Screening

Metrion has developed validated screening assays against an extensive panel of ion channel cell lines using a variety of high quality ion channel screening platforms with a range of throughput capabilities.

Cardiac Safety Screening

Metrion offers screening services against a premium panel of validated Comprehensive in Vitro Proarrhythmia Assay (CiPA) compliant human cardiac ion channel screening assays, which includes hERG.

Neuroscience Assays

Metrion offers a number of neuroscience-related ion channel screening assays and platforms. These neuronal ion channel screening assays can be used for native tissue and species selectivity testing, as well as more general neurotoxicology screening of hits and lead candidates.

Translational Assays

Metrion are developing a number of phenotypic assays to aid the translation of in vitro cardiac safety and neuroscience data to the preclinical stage. Assays and platforms include conventional electrophysiology, microelectrode array and impedance measurement.

Our Facilities

Metrion is located within the Cambridge bio cluster, one of Europe’s largest bioscience research hubs. Our state of the art laboratories at Granta Park house high quality facilities for native and engineered cell line and induced pluripotent stem cell culture, a comprehensive suite of automated patch clamp platforms, multiple manual patch clamp rigs, fluorescence-based screening capability and laboratory data management and reporting systems.

Latest News

Metrion Biosciences closes £2.7m new equity financing

Sophie Rose2021-04-06T07:59:45+00:00April 6th, 2021|Tags: drug discovery, expansion, financing, funding, investment, ion channels|

Metrion Biosciences closes £2.7m new equity financing • Financing led by Gresham House Ventures • Funds to be used [...]

Metrion Biosciences appoints John Montana as Non-Executive Director

Sophie Rose2021-02-09T09:05:37+00:00February 9th, 2021|Tags: contract research, drug discovery, ion channels|

Metrion Biosciences appoints John Montana as Non-Executive Director Expansion of the Board of Directors will support the company’s further [...]

Metrion Biosciences and Sosei Heptares to Explore Structure-based Drug Discovery (SBDD) Approaches to Ion Channels through Strategic Technology Collaboration

Sophie Rose2021-02-01T08:45:23+00:00February 1st, 2021|Tags: drug discovery, GPCRs, Ion Channel Drug Discovery, ion channels, Life Sciences, structure based drug design|

Metrion Biosciences and Sosei Heptares to Explore Structure-based Drug Discovery (SBDD) Approaches to Ion Channels through Strategic Technology Collaboration [...]

Load More Posts